Born in 1943 during World War 2, Larisa Rudenko grew up in Zaporozh\'ye, in southeast Ukraine. Having lost her father during the war, she was raised by her mother, a paediatrician, and spent many early days queuing for food rations. Later, things improved and they were able to take family holidays to Crimea. "I saw many unhappy children in wheelchairs there, and mother told me they had polio and there was no treatment", she tells *The Lancet Infectious Diseases*. "I wanted to help those children. My mother said that American and Russian scientists were working together on a vaccine to help prevent this horrible disease."

After high school she decided to enter medical school in Leningrad (today St Petersburg). She was thrilled to attend a lecture by the polio vaccine creator Anatoly Smorodintsev who was head of the virology department at the Institute of Experimental Medicine of the Russian Academy of Sciences. She asked him nervously if she could work there to learn basic virology. He said yes, and the rest is history. At that time (the 1970s) cold-adapted live influenza vaccines were being clinically tested at her institute. "These were amazing times, because many foreign scientists, including Hilary Koprowski and Robert Chanock visited our department, and we met them and attended their lectures", she recalls.

After graduation, Rudenko completed her PhD on the development of a live oral adenovirus vaccine, under the guidance of Smorodintsev. Then, together with Galina Alexandrova, she worked on a new generation of live attenuated influenza vaccines (LAIV) using the reassortment method for preparing vaccines. They also collaborated with the US Centers for Disease Control and Prevention (CDC) and their advanced technology to fully characterise the master donor strains.

Their team used the reassortment method to prepare the various vaccine strains, and coordinated 8 years of clinical trials including 120 000 children and later older and elderly adults. These studies established the safety, immunogenicity and effectiveness LAIV and the world\'s first LAIV was registered in the former USSR in 1987.

Although inactivated influenza vaccines have dominated US markets, American scientists showed interest in Russian LAIVs. Other trials of LAIVs were conducted in collaboration with CDC and the University of Michigan, including among schoolchildren in Novgorod and elderly in the Leningrad. These trials changed the opinions of American experts, since LAIV establish herd immunity among the non-vaccinated, whereas inactivated forms do not. Despite this, LAIV were only approved and registered in the USA in 2003. They remain in use in the USA and many European countries today.

While her research on LAIV continues, Rudenko\'s other major focus has been as an expert for WHO\'s Global Pandemic Preparedness Plan (GAP). LAIV was included in the GAP as a vaccine which, in the event of a pandemic, can be made much more quickly and in larger quantities compared with inactivated vaccines.

Over the past decade, Rudenko\'s team has developed all of WHO\'s recommended potentially pandemic influenza virus candidates of the H1, H2, H5N1, H7N3, H7N9 subtypes, which underwent preclinical testing and phase I clinical trials. Rudenko then worked with WHO to transfer the technology to LAIV producers in other countries, with licenses granted to companies in Thailand, India, and China.

Rudenko believes that the next influenza pandemic could be caused by the H2N2 type that spread through Singapore in 1957. "Most people alive today would have no immunity to this strain," she explains. "However, it is a human virus with a human receptor. It could be virulent again. Our institute has developed all the reassortants for this strain. If it appears, we will be ready."

On the COVID-19 crisis, Rudenko needs to see more evidence before deciding if it has escaped from a live animal market, a laboratory, or come from another source. "COVID-19 could come back every winter until we find a vaccine", she says. However, always keen to emphasize the positive, she says that "coronavirus has really focused the world\'s attention on the importance of vaccines and when a vaccine will arrive". Her own team has begun work on a nasally applied double vaccine to combat influenza and the novel coronavirus. She estimates 2-3 years are needed to establish if it is safe and efficacious.

In addition to her research, Rudenko has been the mentor for many young scientists at her institution, with the latest generation inspiring her with their knowledge of new techniques in biotechnology and molecular biology and helping develop LAIVs that are more broadly protective. Outside the laboratory, she loves to immerse herself in culture, including visiting the opera.

"I first met Larisa Rudenko at a meeting on influenza vaccines, at the beginning of the conceptualisation of WHO Global Action Plan", says Marie-Paule Kieny, director of research at Inserm, Paris, France, and former assistant director-general at WHO. "By bringing the discussion back to science, she convinced most experts and LAIV became WHO\'s vaccine of choice in case of a pandemic. Following this, Larisa also became a friend and a role model for me, for her strength. energy, determination, and dedication to science, public health, and her team."
